title: Factors in the development of a liver transplantation programme: experience of 100 consecutive transplantations in Milan's Niguarda Hospital.
abstract: From December 1985 to December 1990, 100 liver orthotopic transplantations (OLTX) were performed in 89 adults with cirrhosis and various other liver diseases; eight patients had two transplants and three of these had three transplants. Organ perfusion was done with Eurocollins in the first 30, then with UW solution. Immunosuppressants were a combination of cyclosporin A and steroids for the first 30 patients, and then a combination of antilymphocyte globulin, azathioprine, methylprednisolone and cyclosporin A. The OLTXs were examined as a whole and also divided into two groups, one for 1985-88 and one for 1989-90. The cumulative survival was 63% after 12 months, 40% after 36 and 42 months. It was poor for the patients who received transplants between 1985 and 1988, but for the second group, survival was improved to 78% after 12 and 18 months. For neoplastic patients, overall survival was 49% after 18 months and 23% after 36 and 42 months. In the second group it was markedly better (83% after 18 months). The recurrence rate for patients surviving more than three months was 17% for hepatocellular carcinoma and 50% for cholangiocarcinoma. Five patients (38%) out of 13 HBsAg-positives before the transplant and surviving more than three months had recurrent hepatitis-B virus. The remaining eight patients are HBsAg negative at present. The improved actuarial survival for the second group is accounted for by the better surgical and intensive care given now and the methodological differences.
authors.affiliation: Centro di Epatologia, Ospedale Niguarda Cà Granda, Milano, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Bettale
authors.forename: L
authors.initials: L
authors.lastname: De Carlis
authors.forename: A
authors.initials: A
authors.lastname: Alberti
authors.forename: L
authors.initials: L
authors.lastname: Dughetti
authors.forename: P
authors.initials: P
authors.lastname: Rizzi
authors.forename: G
authors.initials: G
authors.lastname: Rondinara
authors.forename: L
authors.initials: L
authors.lastname: Belli
authors.forename: E
authors.initials: E
authors.lastname: Del Favero
authors.forename: L
authors.initials: L
authors.lastname: Belli
authors.forename: G
authors.initials: G
authors.lastname: Idéo
mesh_terms: D000328:Adult; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007558:Italy; D008107:Liver Diseases / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology / Q000379:methods* / Q000401:mortality; D011182:Postoperative Care; D011183:Postoperative Complications / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D011379:Prognosis; D013997:Time Factors; D009927:Tissue and Organ Procurement / Q000379:methods*; D014181:Transplantation Immunology / Q000187:drug effects / Q000276:immunology*
chemical_list: D007166:Immunosuppressive Agents